Actuate Therapeutics, Inc. (ACTU)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$1.48+8.03%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · ACTU
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Focus on developing oral tablet formulation of elraglusib to improve patient convenience, broaden clinical utility, and optimize exposure in multiple cancer indications.
Newly stated in 2026-Q1. Management announced FDA clearance of IND for oral elraglusib and plans to initiate Phase 1/2 study in 2H 2026 targeting multiple solid tumors. No revenue or profit data available yet; clinical development is at an early stage with no financial delivery to date.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 2 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated neutral grew net income 51% of the time over the next year (vs 41% for the rest of the cohort, n=13363).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“Advancing the elraglusib oral tablet is an important element to the success of our overall development strategy.”
Obtain necessary funding to continue operations past July 2026 amid ongoing cash burn and operating losses.
Stated in 2 of last 2 quarters. Management disclosed need for additional capital beyond July 2026 amid ongoing negative operating cash flow ($-5.0M in 2026-Q1, $-4.4M in 2026-Q2) and net losses ($-5.6M and $-4.9M respectively). The trajectory shows persistent cash burn and losses, consistent with management's warnings about capital requirements.
“Our financial condition raises substantial doubt as to our ability to continue as a going concern.”
“We require additional capital to finance our operations beyond July 2026.”
Appoint experienced industry veteran Martin Huber, MD to newly created Board seat to support oncology drug development and commercialization.
Newly stated in 2026-Q1. Management announced appointment of Martin Huber, MD to the Board as a strategic priority to enhance leadership and support clinical and commercial advancement of elraglusib. This is a one-time event with no direct financial metrics but signals focus on talent and governance.
“Director Martin Huber, MD joins Board of Directors to strengthen strategic and execution capabilities.”
Control and reduce operating losses and negative cash flow to improve financial stability.
Expand the Board of Directors and appoint new leadership to strengthen governance.
Over the trailing year it converted 0.77x of net income into operating cash flow.
Not enough signal yet.
Not enough signal to read sensitivity to the broad stock market, the US dollar, Fed net liquidity, real (inflation-adjusted) rates, long-term interest rates (low R² over the window).
8 material management or governance events in the past 24 months, led by capital-allocation actions. Historically, Health Care names rated neutral grew net income 53% of the time over the next year (vs 49% for the rest of the cohort, n=5275).
Not investment advice. As of 2026-09-04.